The COGCOV Study in ICU Patients

East Limburg Hospital

Status: Completed

Conditions: Cognitive Impairment; Covid19

Treatments: Behavioral: Neurocognitive assessment

Study type: Interventional

Funder types: Other

Identifiers

NCT04593069

COGCOV

Details and patient eligibility

About

Acute Respiratory Distress syndrome (ARDS) is a pulmonary systematic inflammatory response, leading to acute respiratory failure with hypoxia and/or hypercarbia. COVID-19 evokes a viral pneumonia, which may result in ARDS as well. It is not yet clear if COVID-19 disease behaves like the typical ARDS. Corona virus causes primarily deep hypoxia. Hypoxia, on its own, can lead to long term cognitive impairment. However, critical illness also affects long-term neurocognitive functioning. The investigators will be researching the possibility of long-term cognitive impairment in COVID-19 ICU patients, in comparison with reference values of a healthy population as well as the values measured in critically ill patients, admitted not only for respiratory reasons.

Full description

The investigators will conduct a single centre, prospective cohort study. COVID-19 patients from the Ziekenhuis Oost-Limburg cohort will be contacted by phone 6 months after admission at the ICU. Patients will be asked to participate in a study surrounding long term symptoms of COVID-19. When consent is given by the patiënt, the experimenter will conduct a short questionnaire over the phone with the patient or relative that is present at the time of the call. If the participant is fluent in Dutch, the experimenter will ask permission to visit their home to conduct more testing.

Enrollment: 70 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Admitted to the intensive care unit of Ziekenhuis Oost-Limburg
• Being hospitalized between March 2020 and May 2020, and therefore being admitted 6 months prior to the study
• The reason of hospitalization was COVID-19 disease

Exclusion criteria

• No willingness to participate, and therefore not having signed the informed consent

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

70 participants in 1 patient group

COVID-19 patients

Other group

Description:

Neurocognitive impairment in COVID-19 patients

Treatment:

Behavioral: Neurocognitive assessment